Back to Trial

Oracle Runs

Oracle findings and outcome history for Study of ALTO-101 in Patients With Schizophrenia (NCT06502964).

Runs
2
Findings
2
Latest Run
Apr 3, 2026, 4:05 PM
Resolution Evidence
Outcome
NO
Status
Resolved
Settlement Date
4/3/26 UTC
Executive Summary

Sponsor topline readout for this exact Phase 2 ALTO-101 schizophrenia/CIAS study clearly frames the outcome as negative: it says the trial did not achieve statistical significance on the primary endpoint, did not achieve significance on primary EEG or cognitive endpoints, and Alto will not independently advance ALTO-101 in CIAS.

Sources
Sponsorinvestors.altoneuroscience.com4/1/26
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

Company states ALTO-101 'did not achieve statistical significance on primary endpoint' and 'did not achieve statistical significance on primary EEG or cognitive endpoints'; Alto does not plan to independently advance ALTO-101 in CIAS.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NOAccepted98% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Sponsor topline readout for this exact Phase 2 ALTO-101 schizophrenia/CIAS study clearly frames the outcome as negative: it says the trial did not achieve statistical significance on the primary endpoint, did not achieve significance on primary EEG or cognitive endpoints, and Alto will not independently advance ALTO-101 in CIAS.

Found Apr 3, 2026, 4:05 PMOutcome date Apr 1, 2026, 12:00 AMReviewed Apr 3, 2026, 5:19 PM
Sponsorinvestors.altoneuroscience.comApr 1, 2026, 12:00 AM
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
Company states ALTO-101 'did not achieve statistical significance on primary endpoint' and 'did not achieve statistical significance on primary EEG or cognitive endpoints'; Alto does not plan to independently advance ALTO-101 in CIAS.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific efficacy readout is publicly available yet. Sponsor materials in March 2026 still say ALTO-101 Phase 2 topline data are only expected around end of 1Q 2026, and an external tracker pulling ClinicalTrials.gov still lists NCT06502964 as ongoing with no actual reporting date. Without a public readout, outcome cannot be classified positive or negative.

Found Apr 1, 2026, 6:53 PMReviewed Apr 1, 2026, 7:03 PM
Sponsorinvestors.altoneuroscience.comMar 16, 2026, 12:00 AM
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
Company said ALTO-101 topline Phase 2 proof-of-concept data are expected around the end of 1Q 2026; it also describes the trial as ongoing and notes February 2026 enrollment completion.
Web Searchfdaaa.trialstracker.netMar 26, 2026, 12:00 AM
NCT06502964: An ongoing trial by Alto Neuroscience
FDAAA TrialTracker page states the trial is ongoing, results status is ongoing, and actual reporting date is none, based on ClinicalTrials.gov data last checked March 26, 2026.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle ReviewApr 3, 2026, 5:19 PM

Will the results be positive?

PendingtoNOcurrentNO
GPT-5.4 (OpenAI)98% confidenceReviewed Apr 3, 2026, 5:19 PM

Sponsor topline readout for this exact Phase 2 ALTO-101 schizophrenia/CIAS study clearly frames the outcome as negative: it says the trial did not achieve statistical significance on the primary endpoint, did not achieve significance on primary EEG or cognitive endpoints, and Alto will not independently advance ALTO-101 in CIAS.